We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
CVS Health (CVS) Ascends While Market Falls: Some Facts to Note
Read MoreHide Full Article
In the latest trading session, CVS Health (CVS - Free Report) closed at $74.03, marking a +2.82% move from the previous day. The stock exceeded the S&P 500, which registered a loss of 0.01% for the day. Meanwhile, the Dow experienced a rise of 0.03%, and the technology-dominated Nasdaq saw an increase of 0.17%.
Prior to today's trading, shares of the drugstore chain and pharmacy benefits manager had lost 9.83% lagged the Medical sector's loss of 1.67% and the S&P 500's gain of 0.78%.
Analysts and investors alike will be keeping a close eye on the performance of CVS Health in its upcoming earnings disclosure. The company's earnings report is set to go public on February 10, 2026. The company is predicted to post an EPS of $0.98, indicating a 17.65% decline compared to the equivalent quarter last year. Meanwhile, the Zacks Consensus Estimate for revenue is projecting net sales of $102.88 billion, up 5.29% from the year-ago period.
CVS's full-year Zacks Consensus Estimates are calling for earnings of $6.65 per share and revenue of $399.34 billion. These results would represent year-over-year changes of +22.69% and 0%, respectively.
Investors should also note any recent changes to analyst estimates for CVS Health. Recent revisions tend to reflect the latest near-term business trends. As a result, we can interpret positive estimate revisions as a good sign for the business outlook.
Our research suggests that these changes in estimates have a direct relationship with upcoming stock price performance. To take advantage of this, we've established the Zacks Rank, an exclusive model that considers these estimated changes and delivers an operational rating system.
The Zacks Rank system, ranging from #1 (Strong Buy) to #5 (Strong Sell), possesses a remarkable history of outdoing, externally audited, with #1 stocks returning an average annual gain of +25% since 1988. Over the last 30 days, the Zacks Consensus EPS estimate has moved 0.08% higher. CVS Health is holding a Zacks Rank of #3 (Hold) right now.
With respect to valuation, CVS Health is currently being traded at a Forward P/E ratio of 10.06. This valuation marks a discount compared to its industry average Forward P/E of 16.9.
Also, we should mention that CVS has a PEG ratio of 0.66. Comparable to the widely accepted P/E ratio, the PEG ratio also accounts for the company's projected earnings growth. The Medical Services industry had an average PEG ratio of 1.75 as trading concluded yesterday.
The Medical Services industry is part of the Medical sector. With its current Zacks Industry Rank of 182, this industry ranks in the bottom 26% of all industries, numbering over 250.
The Zacks Industry Rank evaluates the power of our distinct industry groups by determining the average Zacks Rank of the individual stocks forming the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
You can find more information on all of these metrics, and much more, on Zacks.com.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
CVS Health (CVS) Ascends While Market Falls: Some Facts to Note
In the latest trading session, CVS Health (CVS - Free Report) closed at $74.03, marking a +2.82% move from the previous day. The stock exceeded the S&P 500, which registered a loss of 0.01% for the day. Meanwhile, the Dow experienced a rise of 0.03%, and the technology-dominated Nasdaq saw an increase of 0.17%.
Prior to today's trading, shares of the drugstore chain and pharmacy benefits manager had lost 9.83% lagged the Medical sector's loss of 1.67% and the S&P 500's gain of 0.78%.
Analysts and investors alike will be keeping a close eye on the performance of CVS Health in its upcoming earnings disclosure. The company's earnings report is set to go public on February 10, 2026. The company is predicted to post an EPS of $0.98, indicating a 17.65% decline compared to the equivalent quarter last year. Meanwhile, the Zacks Consensus Estimate for revenue is projecting net sales of $102.88 billion, up 5.29% from the year-ago period.
CVS's full-year Zacks Consensus Estimates are calling for earnings of $6.65 per share and revenue of $399.34 billion. These results would represent year-over-year changes of +22.69% and 0%, respectively.
Investors should also note any recent changes to analyst estimates for CVS Health. Recent revisions tend to reflect the latest near-term business trends. As a result, we can interpret positive estimate revisions as a good sign for the business outlook.
Our research suggests that these changes in estimates have a direct relationship with upcoming stock price performance. To take advantage of this, we've established the Zacks Rank, an exclusive model that considers these estimated changes and delivers an operational rating system.
The Zacks Rank system, ranging from #1 (Strong Buy) to #5 (Strong Sell), possesses a remarkable history of outdoing, externally audited, with #1 stocks returning an average annual gain of +25% since 1988. Over the last 30 days, the Zacks Consensus EPS estimate has moved 0.08% higher. CVS Health is holding a Zacks Rank of #3 (Hold) right now.
With respect to valuation, CVS Health is currently being traded at a Forward P/E ratio of 10.06. This valuation marks a discount compared to its industry average Forward P/E of 16.9.
Also, we should mention that CVS has a PEG ratio of 0.66. Comparable to the widely accepted P/E ratio, the PEG ratio also accounts for the company's projected earnings growth. The Medical Services industry had an average PEG ratio of 1.75 as trading concluded yesterday.
The Medical Services industry is part of the Medical sector. With its current Zacks Industry Rank of 182, this industry ranks in the bottom 26% of all industries, numbering over 250.
The Zacks Industry Rank evaluates the power of our distinct industry groups by determining the average Zacks Rank of the individual stocks forming the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
You can find more information on all of these metrics, and much more, on Zacks.com.